Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy

Transplantation

Volumn 95, Issue 10, 2013, Pages 1259-1262

  Larsen, Christopher P ^a,b   Walker, Patrick D ^a,b  

^a Nephropath   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

De novo glomerulonephritis; Kidney transplant; Membranous glomerulopathy; PLA2R; Recurrent glomerulonephritis

Indexed keywords

COMPLEMENT COMPONENT C4D; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; PHOSPHOLIPASE A2 RECEPTOR;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHRITIS; PRIORITY JOURNAL; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; STAINING;

ADULT; AGED; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS, MEMBRANOUS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, PHOSPHOLIPASE A2; RECURRENCE;

EID: 84878555367     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31828a947b     Document Type: Article

References (24)

1. Briganti EM, Russ GR,McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103.
2. Sprangers B, Lefkowitz GI, Cohen SD, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010; 5: 790.
3. Pirson Y, Ghysen J, Cosyns JP, et al. Aetiology and prognosis of de novo graft membranous nephropathy. Proc Eur Dial Transplant Eur Ren Assoc 1985; 21: 672.
4. El Kossi M, Harmer A, Goodwin J, et al. De novo membranous nephropathy associated with donor-specific alloantibody. Clin Transplant 2008; 22: 124.
5. Lim BJ, Kim MS, Kim YS, et al. C4d deposition and multilayering of peritubular capillary basement membrane in posttransplantation membranous nephropathy indicate its association with antibodymediated injury. Transplant Proc 2012; 44: 619.
6. Honda K, Horita S, Toki D, et al. De novo membranous nephropathy and antibody-mediated rejection in transplanted kidney. Clin Transplant 2011; 25: 191.
7. Beck LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11.
8. Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1137.
9. Debiec H, Martin L, Jouanneau C, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and de novo membranous nephropathy. Am J Trans 2011; 11: 2144.
10. Larsen CP, Messias NC, Silva FG, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor (PLA2R1) staining in renal biopsies. Mod Pathol 2012. doi: 10.1038/modpathol.2012.207 [Epub ahead of print].
11. Doi T, Mayumi M, Kanatsu K, et al. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol 1984; 58: 57.
12. Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004; 19: 574.
13. Haas M. IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis 1994; 23: 358.
14. Kearney N, Podolak J, Matsumura L, et al. Patterns of IgG subclass deposits in membranous glomerulonephritis in renal allografts. Transplant Proc 2011; 43: 3743.
15. Hoxha E, Kneissler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82: 797.
16. Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364: 616.
17. Andresdottir MB, Wetzels JF. Increased risk of recurrence of membranous nephropathy after related donor kidney transplantation. Am J Transplant 2012; 12: 265.
18. Rodriguez EF, Cosio FG, Nasr SH, et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. Am J Transplant 2012; 12: 1029.
19. Walker PD. The renal biopsy. Arch Pathol Lab Med 2009; 133: 181.
20. Walker PD, Cavallo T, Bonsib SM. Practice guidelines for the renal biopsy. Mod Pathol 2004; 17: 1555.
21. Ehrenreich T, Churg J. Pathology of membranous nephropathy. Pathol Annu 1968; 2: 145.
22. Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24: 377.
23. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563.
24. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.